ORPHA:697096
Cryptosporidiosis
Also known as: Cryptosporidium infection
Publications
20,179
Trials
23
Interventional, condition-specific
Researchers
1,262
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
20,179 matched papers (9,363 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationPartial
1 FDA designation (none yet with FDA orphan-indication approval) — e.g. Nitazoxanide Source
- Interventional trialPresent
23 matched on ClinicalTrials.gov (3 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
1
Designation · no FDA orphan-indication approval yet
- FDA Nitazoxanide (Alinia)Cryptosporidiosis · 1996-12-12
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
20,179
20,179 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
20,179 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
9,363 in the last 10 years · low confidence
Phrase hits: 20,179 · MeSH hits: 0
Who's working on it?
1,262
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Li J7 papers · 2026
College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China; Key Laboratory of Quality and Safety Control of Poultry Products, Ministry of Agriculture and Rural Affairs, Zhengzhou 450046, China; International Joint Research Laboratory for Zoonotic Diseases of Henan, Zhengzhou 450046, China.
Papers in Europe PMC - 02Robertson LJ6 papers · 2026
Parasitology, Faculty of Veterinary Medicine, Norwegian University of Life Sciences, Ås, 1433, Norway.
Papers in Europe PMC - 03Hanevik K5 papers · 2026
Department of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway.
Papers in Europe PMC - 04Katzer F5 papers · 2025
Moredun Research Institute, Pentlands Science Park, Penicuik, EH26 0PZ, Scotland, UK.
Papers in Europe PMC - 05Wang Y5 papers · 2026
College of Veterinary Medicine, Inner Mongolia Agricultural University, Hohhot, China.
Papers in Europe PMC - 06Zhang L5 papers · 2026
College of Veterinary Medicine, Henan Agricultural University, Zhengzhou 450046, China; Key Laboratory of Quality and Safety Control of Poultry Products, Ministry of Agriculture and Rural Affairs, Zhengzhou 450046, China; International Joint Research Laboratory for Zoonotic Diseases of Henan, Zhengzhou 450046, China.
Papers in Europe PMC - 07
- 08Ahmed SAA4 papers · 2026
Department of Medical Parasitology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
Papers in Europe PMC - 09Johansen ØH4 papers · 2026
Microbiology Laboratory, Southern Health and Social Care Trust, Portadown, BT63 5QQ, Northern Ireland, UK.
Papers in Europe PMC - 10Karanis P4 papers · 2026
Department of Basic and Clinical Sciences, University of Nicosia Medical School, Nicosia, Cyprus.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
23
interventional trials for this specific condition
23 interventional trials matched this specific condition name; 3 currently recruiting in our sample.
Data as of 11 September 2026
23 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 95.3th percentile).
low confidence · 95.3th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
23 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07388615·RECRUITING·The Effect of Echinacea (Immulant ®) in the Treatment of CRYPTOSPORIDIOSIS in Immunocompromised Children
Not reviewed·Conditions: Cryptosporidium Infection·Matched via name phrase
- NCT07249463·RECRUITING·Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults
Not reviewed·Conditions: Cryptosporidiosis·Matched via name phrase
- NCT06600711·NOT YET RECRUITING·Nitazoxanide for Treatment of Cryptosporidium in Children
Not reviewed·Conditions: Cryptosporidiosis·Matched via name phrase
Observational and natural-history studies
8 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07716410·RECRUITING·A Study to Characterize the Clinical Presentation and Course of Cryptosporidium in Pediatric Participants
Not reviewed·Conditions: Cryptosporidiosis·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 2 · after dedupe 2 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 2 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (2)
- isrctn·ISRCTN38693215·No longer recruiting·First in human study to assess the safety, tolerability and pharmacokinetics of EDI048 in healthy volunteers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN41089957·No longer recruiting·Double-blind, placebo-controlled study of nitazoxanide suspension in the treatment of cryptosporidiosis in children with HIV
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Cryptosporidiosis — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Cryptosporidiosis" OR "Cryptosporidium infection"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Cryptosporidiosis" OR "Cryptosporidium infection"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 23 interventional · 8 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- No Orphanet definition and no Mondo IDs — likely taxonomy scaffolding; confidence capped at low
Ingested 2026-07-27T20:46:59.220Z